LakeShore Biopharma Co., Ltd (LSB)

NASDAQ: LSB · IEX Real-Time Price · USD

0.490

-0.010 (-2.02%)

At close: Jul 19, 2024, 4:00 PM

0.410

-0.080 (-16.31%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

LakeShore Biopharma Income Statement

Financials in millions CNY. Fiscal year is April - March.

Millions CNY. Fiscal year is Apr - Mar.

Year Ending	TTM	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-	687.2	502.95	257.02
Revenue Growth (YoY)	-	36.63%	95.69%	-
Cost of Revenue	-	153.36	117.07	59.66
Gross Profit	-	533.84	385.88	197.36
Selling, General & Admin	-	354.52	293.62	228.82
Research & Development	-	318.7	211.22	94.39
Operating Expenses	-	673.22	504.84	323.21
Operating Income	-	-139.38	-118.96	-125.85
Interest Expense / Income	-	30.86	2.72	29.69
Other Expense / Income	-	112.1	110.05	35.44
Pretax Income	-	-282.34	-231.73	-190.98
Income Tax	-	1.13	4.94	17.45
Net Income	-	-283.47	-236.67	-208.44
Preferred Dividends	-	137.99	130.66	16.61
Net Income Common	-	-421.46	-367.33	-225.05
Shares Outstanding (Basic)	93	93	62	62
Shares Outstanding (Diluted)	-	93	62	62
Shares Change	50.62%	50.51%	-	-
EPS (Basic)	-	-1.56	-1.71	-3.10
EPS (Diluted)	-	-1.56	-1.71	-3.10
Free Cash Flow	-	-235.16	-468.85	-350.85
Free Cash Flow Per Share	-	-2.53	-7.58	-5.67
Gross Margin	-	77.68%	76.72%	76.79%
Operating Margin	-	-20.28%	-23.65%	-48.96%
Profit Margin	-	-61.33%	-73.03%	-87.56%
Free Cash Flow Margin	-	-34.22%	-93.22%	-136.51%
EBITDA	-	-210.37	-194.07	-131.15
EBITDA Margin	-	-30.61%	-38.59%	-51.03%
Depreciation & Amortization	-	41.11	34.94	30.14
EBIT	-	-251.48	-229.01	-161.29
EBIT Margin	-	-36.59%	-45.53%	-62.76%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).